NAVIDEA BIOPHARMACEUTICALS, INC. reports

Company location: Dublin, OH
Fiscal year end: 31 December

NAVIDEA BIOPHARMACEUTICALS, INC. has filed 1,465 SEC EDGAR filings since 07 Feb 1995

Filter by type:
10-K
10-Q
8-K
SC13D
SC13G

SEC filing history

Showing 701-725 of 949 matching filings.

Per page

25

Current page

29

4

4 filing

Filing date: 15 Mar 2013
Reporting date: 13 Mar 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 15 Mar 2013
Reporting date: 13 Mar 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 15 Mar 2013
Reporting date: 13 Mar 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 15 Mar 2013
Reporting date: 13 Mar 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 15 Mar 2013
Reporting date: 13 Mar 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 15 Mar 2013
Reporting date: 13 Mar 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

8-K File 001-35076

FORM 8-K

Filing date: 14 Mar 2013
Reporting date: 13 Mar 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

8-K File 001-35076

FORM 8-K

Filing date: 13 Mar 2013
Reporting date: 13 Mar 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

8-K File 001-35076

FORM 8-K

Filing date: 07 Mar 2013
Reporting date: 06 Mar 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

8-K File 001-35076

FORM 8-K

Filing date: 27 Feb 2013
Reporting date: 21 Feb 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 26 Feb 2013
Reporting date: 21 Feb 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 26 Feb 2013
Reporting date: 21 Feb 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 26 Feb 2013
Reporting date: 21 Feb 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 26 Feb 2013
Reporting date: 21 Feb 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 26 Feb 2013
Reporting date: 21 Feb 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 19 Feb 2013
Reporting date: 15 Feb 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 19 Feb 2013
Reporting date: 15 Feb 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 19 Feb 2013
Reporting date: 15 Feb 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 19 Feb 2013
Reporting date: 15 Feb 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 19 Feb 2013
Reporting date: 15 Feb 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 19 Feb 2013
Reporting date: 15 Feb 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

SC 13G/A File 005-43603

PLATINUM-MONTAUR LIFE SCIENCES, LLC SC 13G A 12-31-2012

Filing date: 19 Feb 2013
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

8-K File 001-35076

CURRENT REPORT

Filing date: 31 Jan 2013
Reporting date: 29 Jan 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

424B5 File 333-173752

RULE 424(B)(5)

Filing date: 31 Jan 2013
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

8-K File 001-35076

FORM 8-K

Filing date: 07 Jan 2013
Reporting date: 01 Jan 2013
SEC evidence: Open document Open filing
Next action: Verify source filing

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .